JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB307148

Anti-Tafazzin/TAZ antibody [EPR26956-58]

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Recombinant Monoclonal Tafazzin / TAZ antibody. Suitable for IP, WB and reacts with Human, Rat, Mouse samples. Cited in 3 publications.

View Alternative Names

EFE2, G4.5, TAZ, TAFAZZIN, Tafazzin, Taz, Protein G4.5

5 Images
Immunoprecipitation - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)
  • IP

Supplier Data

Immunoprecipitation - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Tafazzin/TAZ was immunoprecipitated from 0.35 mg SW-13 (human adrenal gland; cortex epithelial cell) whole cell lysate 10 ug with ab307148 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab307148 at 1/1000 dilution. VeriBlot for IP secondary antibody (HRP) (ab131366) was used at 1/5000 dilution.

Lane 1 : SW-13 (human adrenal gland; cortex epithelial cell) whole cell lysate 10 ug
Lane 2 : ab307148 IP in SW-13 whole cell lysate
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab307148 in SW-13 whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 180 seconds

All lanes:

Immunoprecipitation - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

SW-13 (human adrenal gland; cortex epithelial cell) whole cell lysate 10 μg

Lane 2:

SW-13 whole cell lysate

Secondary

All lanes:

Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/5000 dilution

Observed band size: 30 kDa

false

Exposure time: 180s

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)
  • WB

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST Exposure time : 180 seconds

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

Human colon cancer tissue lysate 20 μg

Lane 2:

Mouse heart tissue lysate 20 μg

Lane 3:

Mouse skeletal muscle tissue lysate 20 μg

Lane 4:

Rat heart tissue lysate 20 μg

Lane 5:

Rat skeletal muscle tissue lysate 20 μg

Lane 6:

NIH/3T3 (mouse embryonic fibroblast) whole cell lysate 20 μg

Lane 7:

RAW 264.7 (mouse elson murine leukemia virus-induced tumor macrophage) whole cell lysate 20 μg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

false

Exposure time: 180s

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)
  • WB

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST Exposure time : Lanes 1, 4 and 5 : 180 seconds, Lanes 2 and 3 : 37 seconds

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

SW-13 (human adrenal gland; cortex epithelial cell) non-mitochondrial fraction 20 μg

Lane 2:

SW-13 mitochondria fraction 20 μg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

false

Exposure time: 180s

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)
  • WB

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

All lanes:

HEK-293 (human embryonic kidney epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

true

Exposure time: 180s

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)
  • WB

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

HeLa (human cervical adenocarcinoma epithelial cell) transfected with scrambled siRNA control whole cell lysate at 20 µg

Lane 2:

HeLa transfected with siRNA specifically targeti Tafazzin/TAZ whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

true

Exposure time: 180s

  • Carrier free

    Anti-Tafazzin/TAZ antibody [EPR26956-58] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR26956-58

Isotype

IgG

Carrier free

No

Reacts with

Human, Mouse, Rat

Applications

WB, IP

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" }, "Mouse": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" }, "Rat": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Tafazzin also known as TAZ is a mitochondrial phospholipid-lysophospholipid transacylase enzyme. It plays a role in the remodeling of cardiolipin a phospholipid found predominantly in the mitochondrial inner membrane. Tafazzin has a molecular mass of approximately 33 kDa. It is expressed in various tissues with higher expression levels found in tissues with high energy demands such as the heart and skeletal muscles.
Biological function summary

Tafazzin is essential for maintaining mitochondrial function and energy production. It is a critical component of the system responsible for cardiolipin metabolism. The enzyme does not work alone; it interacts with other mitochondrial proteins to facilitate the proper composition of cardiolipin species necessary for mitochondrial structural integrity and functionality.

Pathways

Tafazzin serves an important role in various lipid metabolism pathways. It participates in the phospholipid remodeling pathway where it interacts closely with acyltransferases to modify cardiolipin. This interaction is important for mitochondrial processes such as oxidative phosphorylation and energy conversion affecting proteins like cytochrome c oxidase and ATP synthase complex.

Tafazzin mutations are linked to Barth syndrome a rare genetic condition that affects the heart and muscles. This disorder is marked by symptoms including cardiomyopathy muscle weakness and neutropenia. Tafazzin dysfunction interrupts normal cardiolipin remodeling impacting proteins such as cytochrome c which contributes to abnormal energy metabolism seen in the syndrome. Additionally altered Tafazzin activity has connections to mitochondrial dysfunctions observed in some cardiomyopathies.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Acyltransferase required to remodel newly synthesized phospholipid cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL), a key component of the mitochondrial inner membrane, with tissue specific acyl chains necessary for adequate mitochondrial function (PubMed : 12930833, PubMed : 19164547, PubMed : 19700766, PubMed : 26908608, PubMed : 33096711). Its role in cellular physiology is to improve mitochondrial performance (PubMed : 32234310). CL is critical for the coassembly of lipids and proteins in mitochondrial membranes, for instance, remodeling of the acyl groups of CL in the mitochondrial inner membrane affects the assembly and stability of respiratory chain complex IV and its supercomplex forms (By similarity). Catalyzes the transacylation between phospholipids and lysophospholipids, with the highest rate being between phosphatidylcholine (1,2-diacyl-sn-glycero-3-phosphocholine or PC) and CL. Catalyzes both 1-acyl-sn-glycero-3-phosphocholine (lysophosphatidylcholine or LPC) reacylation and PC-CL transacylation, that means, it exchanges acyl groups between CL and PC by a combination of forward and reverse transacylations. Also catalyzes transacylations between other phospholipids such as phosphatidylethanolamine (1,2-diacyl-sn-glycero-3-phosphoethanolamine or PE) and CL, between PC and PE, and between PC and phosphatidate (1,2-diacyl-sn-glycero-3-phosphate or PA), although at lower rate. Not regiospecific, it transfers acyl groups into any of the sn-1 and sn-2 positions of the monolysocardiolipin (MLCL), which is an important prerequisite for uniformity and symmetry in CL acyl distribution. Cannot transacylate dilysocardiolipin (DLCL), thus, the role of MLCL is limited to that of an acyl acceptor. CoA-independent, it can reshuffle molecular species within a single phospholipid class. Redistributes fatty acids between MLCL, CL, and other lipids, which prolongs the half-life of CL. Its action is completely reversible, which allows for cyclic changes, such as fission and fusion or bending and flattening of the membrane. Hence, by contributing to the flexibility of the lipid composition, it plays an important role in the dynamics of mitochondria membranes. Essential for the final stage of spermatogenesis, spermatid individualization (By similarity). Required for the initiation of mitophagy (PubMed : 33096711). Required to ensure progression of spermatocytes through meiosis (By similarity). Exon 7 of human tafazzin is essential for catalysis (PubMed : 19700766).. Isoform 1. Catalyzes the transacylation between lysophosphatidate (such as 1-acyl-sn-glycero-3-phosphate) and phosphatidylglycerol (1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol)) (PubMed : 19700766). Contributes to cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL) remodeling (PubMed : 12930833, PubMed : 19700766).. Isoform 3. Catalyzes the transacylation between lysophospholipids and phospholipids, and plays a fundamental role in cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL) metabolism and remodeling.. Isoform 5. Catalytically inactive.. Isoform 7. Catalytically inactive.
See full target information TAFAZZIN

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Chinese medicine 20:36 PubMed40098188

2025

Chikusetsusaponin IVa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation.

Applications

Unspecified application

Species

Unspecified reactive species

Kai Gao,Wei Zhang,Dong Xu,Meina Zhao,Xingru Tao,Yunyang Lu,Jingwen Wang

Neoplasia (New York, N.Y.) 60:101102 PubMed39674114

2024

USP20 mediates malignant phenotypic changes in bladder cancer through direct interactions with YAP1.

Applications

Unspecified application

Species

Unspecified reactive species

Wensun Chen,Siqi Wu,Yifan Chen,Weijian Li,Yiqing Cao,Yingchun Liang,Xiyu Dai,Xinan Chen,Yilin Chen,Tian Chen,Shenghua Liu,Chen Yang,Haowen Jiang

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11:e2309133 PubMed38225729

2024

Tensile Stress-Activated and Exosome-Transferred YAP/TAZ-Notch Circuit Specifies Type H Endothelial Cell for Segmental Bone Regeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Feng Wang,Shanyu Li,Lingchi Kong,Kai Feng,Rongtai Zuo,Hanzhe Zhang,Yifan Yu,Kunqi Zhang,Yuting Cao,Yimin Chai,Qinglin Kang,Jia Xu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com